Compare PROP & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | NEPH |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 39.0M |
| IPO Year | 2008 | 2004 |
| Metric | PROP | NEPH |
|---|---|---|
| Price | $0.42 | $3.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.50 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 1.1M | 49.6K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 49.06 | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | $7,939,000.00 | ★ $18,789,000.00 |
| Revenue This Year | $85.81 | $17.81 |
| Revenue Next Year | $11.47 | $15.90 |
| P/E Ratio | ★ N/A | $26.08 |
| Revenue Growth | ★ 413.59 | 32.67 |
| 52 Week Low | $0.32 | $2.66 |
| 52 Week High | $2.55 | $6.42 |
| Indicator | PROP | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 37.68 |
| Support Level | $0.38 | $3.19 |
| Resistance Level | $0.44 | $3.78 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.11 | 24.09 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.